May 28, 2009 — A new science advisory from the American Heart Association (AHA)/American Stroke Association (ASA) has given the green light to the use of tissue plasminogen activator (tPA) to treat ...

Adult patients with sickle cell disease (SCD) who experience a stroke caused by a clot (i.e., ischemic strokes or IS) can be treated safely with tissue plasminogen activator (tPA) if they qualify, ...

In the largest report on acute stroke in sickle cell disease to date, researchers at the Medical University of South Carolina and elsewhere provide the first systemic evidence for the safe use of tPA ...

Intravenous recombinant tissue plasminogen activator can be used for the treatment of acute ischemic stroke in the elderly (age ≥80 years) within the NINDS rtPA protocol The study was a prospective ...

Among patients presenting directly to a thrombectomy-equipped center with a large-vessel ischemic stroke, going directly to the endovascular suite and forgoing initial IV thrombolytic therapy provides ...

Tissue plasminogen activator (TPA) can effectively treat patients with acute ischemic stroke, but only if administered within 3 h of stroke onset. This is not always feasible, because patients often ...

Northampton’s Cooley Dickinson Hospital reported 75 percent of eligible patients received the drug. But at Holyoke Medical Center, 96.3 percent of eligible patients -- 26 of 27 -- got the medication ...

LOS ANGELES — Data from the first randomized trial of thrombolysis in patients with mild ischemic stroke and no clear disabling deficit show no evidence of benefit of tissue plasminogen activator (tPA ...

Patients suffering from a stroke are more likely to have improved outcomes and fewer complications when hospitals use standardized guidelines for stroke care during a patient’s admission and discharge ...

CHARLOTTESVILLE, Va., May 23, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for ...